Targeting Systems was started entirely with the help of an SBIR phase I grant from the NIH. The company launched its first product line, Targefect™ within its first year of inception. The company which began as a one person operation now offers over 100 products based a very diverse and strong IP portfolio Targeting Systems has applied it´s expertise in bioluminescence to address challenges in drug discovery, gene expression and stem cell research.